Related Experiment Videos
New therapies for ankylosing spondylitis: etanercept, thalidomide, and pamidronate
John C Davis1, Feng Huang, Walter Maksymowych
1Division of Rheumatology, Department of Medicine, University of California-San Francisco, 533 Parnassus Avenue, Box 0633, San Francisco, CA 94143, USA. jdavis@medicine.ucsf.edu
Rheumatic Diseases Clinics of North America
|September 4, 2003
Abstract:
Ankylosing spondylitis (AS) is the most common of a group of diseases called seronegative spondyloarthropathies. This group of diseases shares common demographic, clinical, and genetic features. This article reviews the rationale, clinical efficacy, and safety reports of etanercept, thalidomide, and pamidronate in the treatment of patients who have AS.